Skip to content

Clinical study on the differences in the effect of lidocaine on alleviating bladder irritation symptoms after ureteral dilation under different administration methods

Clinical study on the differences in the effect of lidocaine on alleviating bladder irritation symptoms after ureteral dilation under different administration methods

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124646
Enrollment
Unknown
Registered
2026-05-14
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ureteral dilation

Interventions

Local anesthesia group:Slowly inject 1% lidocaine injection into the bladder via an indwelling catheter (dose calculated at 1 mg/kg, with a maximum dose not exceeding 400 mg). After the injection, cla
Venous group:Before the end of the ureteral dilation procedure, a single intravenous injection of 1% lidocaine solution (dose same as the local anesthesia group, 1 mg/kg, injection time = 5 minutes) w

Sponsors

Beijing Friendship Hospital Pinggu Campus,Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Aged between 18 and 75; 2.The ureteral dilation was performed for the first time due to urinary calculi, and a ureteral stent needs to be routinely placed after the operation; 3.ASA classification is from Grade I to Grade III; 4.The patient was conscious and could accurately understand the research process, cooperating to complete various scores and follow-ups; 5.The patients and their families gave informed consent, voluntarily participated in this study and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.People allergic to lidocaine or other amide local anesthetics; 2.Patients with severe dysfunction of vital organs such as the heart, liver and kidneys, who are unable to tolerate research drugs or surgeries; 3.Those with a history of epilepsy, central nervous system diseases or mental disorders; 4.Those with bladder lesions themselves that may interfere with the assessment of bladder irritation symptoms; 5.Those who have used drugs that affect bladder function recently (within one month); 6.Pregnant or lactating women; 7.Those who are unable to communicate effectively or refuse to cooperate to complete the follow-up and scoring.

Design outcomes

Primary

MeasureTime frame
The effective rate of analgesia 0.5 hours after the operation;

Secondary

MeasureTime frame
VAS score2 hours after the operation;The time of the first voluntary urination;VAS score 6 hours after the operation;The occurrence of adverse reactions;VAS score24 hours after the operation;The usage of anti-inflammatory and analgesic suppositories;

Countries

China

Contacts

Public ContactXiaoqian Wang

Beijing Friendship Hospital Pinggu Campus,Capital Medical University

wangxqbaoding@163.com+86 151 2896 7199

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026